CONCORDBIO vs MANKIND: Stock Comparison
MANKIND PHARMA is the larger company by market capitalisation. CONCORD BIOTECH shows a higher ROE, a higher dividend yield and lower leverage, while MANKIND PHARMA shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CONCORDBIO leads 7; MANKIND leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | CONCORDBIO | MANKIND |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | CONCORDBIO | MANKIND |
|---|---|---|
| Live Price | ₹1,240.6 | ₹2,520 |
| Day Change | 0.81% | 2.05% |
| Volume | 50,434 | 2.59 L |
| 52-Week High | ₹1,615 | ₹2,642 |
| 52-Week Low | ₹987 | ₹1,909.7 |
| Distance from 52W High | -23.18% | -4.62% |
Valuation
| Metric | CONCORDBIO | MANKIND |
|---|---|---|
| Market Cap | ₹13,027 Cr | ₹1.04 L Cr |
| P/E Ratio | 45.59x | 45.19x |
| P/B Ratio | 6.2x | 5.78x |
| EPS | ₹26.71 | ₹13.9 |
| Book Value | ₹195.37 | ₹401 |
| Dividend Yield | 0.6% | 0% |
Growth
| Metric | CONCORDBIO | MANKIND |
|---|---|---|
| Revenue Growth (TTM YoY) | -24.1% | 11.8% |
| EPS Growth (TTM YoY) | -37% | 31.7% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | CONCORDBIO | MANKIND |
|---|---|---|
| ROE | 13.03% | 11.7% |
| ROCE | 13.09% | 10.93% |
| Net Margin | 24.6% | 13.34% |
| Operating Margin | 33.33% | 20.73% |
| Debt to Equity | 0x | 0.38x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | CONCORDBIO | MANKIND |
|---|---|---|
| Promoter Holding | 44.09%▲ 0.01 pp | 72.62%▼ 0.01 pp |
| FII Holding | 7.28%▼ 0.24 pp | 9.37%▼ 0.08 pp |
| DII Holding | 10.95%▲ 1.59 pp | 15.56%▲ 0.17 pp |
| Public Holding | 37.68%▼ 1.35 pp | 2.45%▼ 0.08 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CONCORD BIOTECH and MANKIND PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.